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Abstract: Adiponectin is one of the most bioactive substances secreted by adipose tissue 
and is involved in the protection against metabolic syndrome, artherosclerosis and type II 
diabetes. Research into the use of adiponectin as a promising drug for metabolic 
syndromes requires production of this hormone in high quantities considering its molecular 
isoforms. The objective of this study is to produce recombinant human adiponectin by 
Pichia pastoris (P-ADP) as a cheap and convenient eukaryotic expression system for 
potential application in pharmaceutical therapy. For comparison, adiponectin was also 
expressed using the Escherichia coli (E-ADP) expression system. Adiponectin was 
constructed by overlap-extension PCR, and cloned in standard cloning vector and hosts. 
Recombinant expression vectors were cloned in the P. pastoris and E. coli host strains, 
respectively. SDS-PAGE and western blotting were used to detect and analyse expressed 
recombinant protein in both systems. Adiponectin was purified by affinity chromatography 
and quantified using the Bradford Assay. The results of this study indicated that P-ADP 
quantity (0.111 mg/mL) was higher than that of E-ADP (0.04 mg/mL) and both were 
produced in soluble form. However, P-ADP was able to form high molecular weights of 
adiponectin molecules, whilst E-ADP was not able to form isoforms higher than trimer. In 
addition, P-ADP was more active in lowering blood glucose compared with E-ADP. The 
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two types of proteins were equally efficient and significantly decreased blood triglyceride 
and increased high density lipoprotein. We conclude that P. pastoris is able to produce 
high quantity of bioactive adiponectin for potential use in treatment of metabolic syndromes. 
Keywords: adiponectin; Pichia pastoris; E.coli; recombinant protein; biological activity 
 
1. Introduction  
Adipose tissue has been shown to play an important role in the regulation of body energy 
homeostasis and metabolism, lipid storage and as an endocrine organ. One of the most important 
factors secreted by adipose tissue is adiponectin (ADP) [1]. There is obvious correlation between 
plasma ADP levels and metabolic syndrome [2–4] and various studies have shown a noticeable 
decrease in ADP levels in patients with obesity, type II diabetes and with the accumulation
 
of visceral 
adipose tissue [5–7]. In recent years, ADP has attracted much consideration as a novel therapeutic tool 
for diabetes and metabolic syndromes.  
It is generally accepted that the choice of heterologous protein expression system has profound 
influence on characteristics of the recombinant protein [8]. Compared to prokaryotic expression 
systems like Escherichia coli, the advantages of eukaryotic expression system such as the 
methylotrophic yeast Pichia pastoris are many. These advantages include an efficient recombinant 
protein secretion pathway for ease of purification, the availability of eukaryotic post-translational 
modifications, fast growth on economic salt-based media and little risk of contamination with  
endo-toxins or oncogenic or viral DNAs [9]. Exclusively, P. pastoris has a very low maintenance 
energy
 
demand, which makes it well suited for high cell density fermentation. The availability of 
strong and tightly regulated
 
promoters makes this yeast a very attractive host for recombinant
 
protein 
production [10].  
Different groups have reported expression of different versions of human ADP in various types of 
host. The globular domain of ADP have been successfully expressed in E. coli and P. Pastoris [11,12] 
whilst the full-length protein have been expressed in E. coli and in baculovirus based expression 
systems [13]. Each reported varying degree of success in terms of yield and functionality of the 
recombinant protein. However, the expression of recombinant adiponectin in P. pastoris and 
evaluation of its activity have not been fully investigated. Therefore, in this study we examined the 
activity of recombinant adiponectin which was produced by P. pastoris (P-ADP) compared with that 
produced by E. coli (E-ADP). The results of this study showed that P-ADP underwent post translation 
modification and has better bioactivity than E-ADP. In addition, P. pastoris expression system was 
efficient in producing high quantity and quality of biologically active recombinant ADP compared 
with E. coli expression system. 
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2. Results  
2.1. Construction and Cloning of Human ADP in P. pastoris and E. coli 
The results of the overlap-extension PCR showed that the full-length ADP (735 bp) was 
successfully obtained using this procedure. The full length ADP encoded variable, collagenous and 
globular
 
domains of ADP (Figure 1). Cloning of ADP downstream of the signal peptide and MBP 
sequences was successful in producing MBP-E-ADP periplasm fusion protein. Similarly, cloning of 
ADP in pPICZαA vector after the α-factor signal peptide was successful in producing 6× His tagged  
P-ADP that would eventually be secreted extracellularly. 
Figure 1. In vitro construction of ADP fragment using overlap-extension PCR. ADP 
fragment was amplified by PCR through 32 cycles include denaturing step (95 °C for 45 s), 
annealing step (60 °C for 45 s) and elongation step (72 °C for 1 min). The two fragments 
were then purified and joined through 10 cycles of overlap-extension PCR include 
denaturing step at 95 °C for 45 s, annealing step at 60 °C for 45 s and elongating step at 
72 °C for 1 min. L1: PCR product of exon 2 (204 bp). L2: PCR product of exon 3 (531 bp). 
L3: the full length of ADP fragment (734 bp). M: 100 bp DNA marker. 
 
2.1. Expression of ADP in E. coli and Protein Purification  
ADP was inserted downstream of the mal E of E. coli that encodes the maltose binding protein 
(MBP) resulting in the expression of an MBP fusion protein. As such, the amylose resin column 
system was used for purification of this fusion protein. SDS-PAGE results indicated that the expected 
size of the fusion protein was approximately 75 kDa (Figure 2). As mentioned previously, MBP was 
linked to adiponectin protein by four amino acids (ile-glu-gly-arg). This link can be recognized by 
Factor Xa for cleavage and separation of adiponectin from MBP. The expected size of adiponectin 
after digestion with Factor Xa was approximately 30 kDa (Figure 3).  
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Figure 2. SDS-PAGE analysis of adiponectin expression before and after induction with 
IPTG. The expected size of fusion protein (MBP-adionectin) was approximately 75 kDa 
and this can be seen in reference to the protein marker (M). The band of fusion protein was 
faint before induction (L1). However, after induction with IPTG, the fusion protein was 
more detectable (arrow) after 2 h (L2) and 3 h (L3). 
 
 
It is shown that there was no clear difference between protein samples after digestion with Factor 
Xa for different time points. In the positive control that contains crude protein digested with Factor Xa, 
the estimated molecular weight of MBP was higher than that of the adiponectin protein and this protein, 
like other E. coli native proteins, was totally removed after second purification by amylose resin 
column (Figure 3). The second purification was carried out to eliminate MBP residues. This 
purification was performed by passing the fusion protein cleavage product through the hydroxyapatite 
column to remove maltose residues. The eluted protein was then loaded into the amylose resin column 
and the flow through factions were collected. Protein in the flow through was free of MBP protein and 
consists of adiponectin protein with a total amount of 0.04 mg/mL (Figure 3).  
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Figure 3. SDS-PAGE for optimization of Factor Xa digestion. This figure showed that 
there was no clear difference between protein digestion with Factor Xa for 2 h (L1),  
4 h (L2) and 8 h (L3). Digestion of crude protein with Factor Xa showed that the expected 
size for maltose binding protein (MBP) is approximately 45 kDa whereas the expected size 
of adiponectin protein is approximately 30 kDa (L4). 
 
2.3. Expression of ADP in Pichia pastoris and Protein Yield Optimization   
A time course study was performed to determine optimal methanol induction times, maximum yeast 
growth rate and the best time for protein harvesting (Table 1). SDS-PAGE results showed that the 
expression of adiponectin protein was detected from 12 h after the beginning of methanol induction 
until the 96th hour of induction (Figure 4). Western blot analysis corroborated PAGE results with the 
estimated recombinant protein size of approximately 30 kDa (Figure 5). The highest concentration of 
expressed P-ADP protein was 0.11 mg/mL obtained at  60  h after the start of methanol induction  
(Table 1). P-ADP with 6× His tag was subsequently purified by one step affinity chromatography 
nickel column.  
Figure 4. SDS-PAGE of time-course expression shows the exponential increase in band 
(arrow) densities starting from 12 h to 60 h of P-ADP expression after methanol induction.  
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Figure 5. P-ADP molecules were detected by western blot analysis for time course 
expression using adiponectin monoclonal antibody.  
 
Table 1. The differences in the optical density reading, total cells mass and protein 
concentration after methanol induction. 
Hours after methanol 
Induction 
Culture density 
(OD600) 
Total cells mass (g) 
Protein concentration 
(µg/mL) 
12 27.75 1.02 5 
24 36.57 1.49 22 
36 35.5 1.51 25 
48 52.8 1.60 93 
60 49.25 1.60 111 
72 51.33 1.80 78 
86 49.0 1.62 48 
96 43.15 1.78 77 
  
2.4. Analysis of Recombinant Adiponectin Protein Produced by E.coli and P.pastoris 
SDS-PAGE under non-reducing condition was performed to detect the oligomerization process in 
adiponectin protein using anti-adiponectin anti-body. The expected size of the adiponectin monomer 
was approximately 30 kDa for each of the two types of protein. However, the recombinant adiponectin 
protein produced by E. coli showed less oligomers compared with adiponectin protein types that can 
be produced by P. pastoris (Figure 6).  
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Figure 6. SDS-PAGE without denaturing condition showed less oligomers for adiponectin 
protein produced by E. coli compared with that produced by Pichia pastoris. M: Protein 
marker L1: Recombinant adiponectin produced by Pichia pastoris. L2: Recombinant 
adiponectin produced by E. coli. 
 
2.4. Comparison of Biological Activity Between P-ADP and E-ADP 
Comparison of biological activity between P-ADP and E-ADP showed that both types of 
recombinant protein significantly lowered blood glucose throughout the experiment period (Figure 7). 
Additionally, it was also observed that both types of proteins have significant effects on blood lipids 
by decreasing triglyceride levels and increasing HDL levels at the end of the experiment period. 
However, both these proteins showed no significant effect on total cholesterol and LDL levels  
(Figure 8). It is also important to note that P-ADP was significantly more active in lowering blood 
glucose comparing with E-ADP on the experiments conducted above. 
Figure 7. P-ADP and E-ADP significantly lowered blood glucose (t-test, p < 0.01) and there 
was significant difference (t-test, p < 0.05) between P-ADP and E-ADP in lowering blood 
glucose. Data were calculated by mean ± SEM. 
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Figure 8. Effect of P-ADP and E-ADP on lipid profile after four hours from the first 
injection. The two types of protein significantly (t-test, p < 0.01) lowered the triglyceride 
levels, whereas these proteins caused significant increase (t-test, p < 0.05) in HDL levels. 
There were no significant effects on total cholestrol levels or LDL levels . Also, there were 
no significant differences between P-ADP and E-ADP. Data were calculated by mean ± SEM. 
 
3. Discussion 
It has been shown previously that adiponectin functions as regulators of insulin sensitivity, glucose 
homeostasis and lipid metabolism [14–16]. The failure of adiponectin monomers to assemble into 
trimers would result in impaired secretion from the cell, and subsequently results in the diabetic 
phenotype with hypoadiponectinemia, as shown to be true for some adiponectin mutants [17]. 
Therefore, there is a need to be able to produce appropriately functional adiponectin in high quantities 
for pharmaceutical purposes, using cheap and convenient expression systems. 
It is a general fact that quantity and quality of the recombinant protein as well as the cost of 
production are important considerations in producing pharmaceutical therapies. The recombinant 
proteins which are produced by different host cells vary in protein characteristic such as effective 
translation due to codon specificity, post-translational modifications, as well as the size of the resulting 
protein which is dependent on the degree of glycosylation [8]. For instance, certain recombinant 
proteins expressed in E. coli required extra processing steps for denaturation and refolding, in order to 
obtain biologically active forms [18]. Furthermore, recombinant proteins which are produced inside or 
outside host cells differ in the extent of accumulation in inclusion bodies [18]. In previous studies, 
recombinant globular domain of human adiponectin produce by P. pastoris was biologically active [12]. 
However, it was also reported that the full length protein showed higher activity than the shorter form 
(globular domain) [19]. Globular domain adiponectin is also limited in its ability to induce cellular 
response, as it had been shown to only affect one of two types of adiponectin receptors [20]. In view of 
that, we chose P. pastoris as a cheap alternative expression system to extracellularly produce full 
length adiponectin, which are more effective biomolecules, without the need for refolding treatments 
or additional steps of purification. Adiponectin protein produced by E. coli showed good solubility, but 
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the level of post translation modification was lower than that of P. pastoris. The MBP tag was 
important in facilitating the production of soluble protein by E. coli. However, there would then be the 
requirement of additional purification steps to remove MBP. This is definitely disadvantageous 
compared to one step purification in the case of expression in P. pastoris.  
In this study, two important factors facilitated high quantity production of ADP by P. pastoris. 
Firstly, the expression of ADP was driven by the strong and tightly regulated AOX1 promoter. 
Secondly, a time-course study of adiponectin expression enabled us to determine the specific time of 
high expression of recombinant protein and low proteolytic activity. The culture at sixty hours after 
methanol induction yielded 0.111 mg/mL, and this is a reasonably good quantity compared with that 
produced by E. coli (0.1 mg/mL [11], 0.04–0.08 mg/mL [13]), 0.01 mg/mL by baculovirus [13] and 
0.05 mg/mL globular adiponectin expressed by P. pastoris [12]. The SDS-PAGE and western blotting 
analysis established that the approximated size of human adiponectin protein obtained in this study 
was similar to those previously reported [11,17]. 
Consistent with previous findings [19,21]
 
ADP was effective in lowering blood glucose and 
triglycerides. ADP as full length proteins has the ability to effectively influence both AdipoR1 and 
AdipoR2 receptors, which stimulate glucose uptake and fatty acids oxidation [22,23]. Likewise, ADP 
has also been shown to be beneficial on blood lipid profile through decreasing triglycerides and 
increasing HDL. As such, our findings and results from several other studies corroborate the 
suggestion that ADP potentially has anti-atherogenic properties [24–26].  
4. Experimental Section 
4.1. Culture Media 
Escherichia coli strain JM109 and TB1 were cultured in standard LB broth and selective LB-agar. 
The selective LB-agar medium contains 2% agar, 0.5 mM isopropylthiogalactoside (IPTG), 80 µg/mL 
of 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal) and 100 µg/mL ampicillin. E. coli 
strain TOP10 was cultured in low salt LB medium (LSLB) and LSLB-Agar with zeocin™ (salt 
concentration < 90 mM and pH 7.5 for zeocin to be active). LSLB medium contains 1% peptone, 0.05% 
NaCl, 0.5% yeast extract and 1.5% agar with 25 g/mL Zeocin™ for solid medium. 
Escherichia coli expression strain TB1 were cultured in LB rich medium containing 100 μg/mL 
ampicillin, 1% peptone, 0.5% yeast extract, 0.5% NaCl and 0.2% dextrose. Whereas, P. pastoris were 
cultured in YPD broth, containing 2% peptone, 1% yeast extract, 2% dextrose and 100 mg/L Zeocin™ 
YPDS-agar was made by including 2% agar and 18% sorbitol. For gene expression purposes, the 
BMMY and BMGY media was used. These buffered complex media contained 2% peptone, 1% yeast 
extract, 4 × 10
−5
 % biotin, 1.34% yeast nitrogen base, 0.1 M potassium phosphate buffer, pH 6.0 and 1% 
glycerol for BMGY growth medium, or 1% methanol for BMMY induction medium.  
 
4.2. Gene Construction and Cloning 
Adiponectin gene reference sequence was obtained from GenBank under the reference number 
NC_000003.11. Exon 2 and exon 3 of the ADP fragment was amplified individually by polymerase 
chain reaction (PCR). The PCR conditions through 32 cycles were 95 °C for 45 s as denaturing step, 
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60 °C for 45 s as an annealing step and 72 °C for 1 min as an elongation step. The two fragments were 
then joined by overlap-extension PCR. The reaction conditions of an overlap-extension PCR through 
10 cycles were denaturing step at 95 °C for 45 s, annealing step at 60 °C for 45 s and elongating step at 
72 °C for 1 min. The pMAL™-p4 vector (New England Biolabs, UK) was used to produce ADP in  
E. coli periplasm. This vector was digested with Xmn I and Hind III restriction enzymes (Promega, 
USA). At the same time, ADP fragment which prepared to express by E. coli was digested with Hind 
III restriction enzyme. The ligation mixture was prepared by adding digested vector and digested ADP 
fragment with DNA ligase and its suitable ligation buffer (New England Biolabs, UK).  
Adiponectin fragment was cloned in pGEM
®
-T cloning vector (Promega, USA). After sequence 
verification, the recombinant plasmid was double digested with EcoRI and NotI restriction enzymes to 
generate fragments with cohesive termini. Digested fragments were purified using the QIAquick Gel 
Extraction kit (Qiagen, USA), as described in the manufacturer’s protocol. To clone in P. pastoris, 
ADP fragment were then ligated to the pPICZαA plasmid which had been digested with EcoRI and 
NotI, followed by phenol-chloroform extraction and ethanol precipitation. Following sequence 
verification, the pPICZαA-ADP recombinant plasmid was linearized with SacI and transformed into 
competent X-33 P. pastoris cells using the EasyComp™ (Invitrogen, Netherlands) procedure.  
4.3. Expression in E. coli 
Single colony of cells containing fusion plasmid was used to inoculate 10 mL of LB broth and 
grown overnight at 37 °C. An overnight culture was used to inoculate one litre of an expression 
medium. The subculture was grown at 37 °C with good aeration (250 rpm shaking) until OD600 was 
approximately 0.5. An aliquot sample of 1 mL was taken as non-induced cells and centrifuged for  
2 min. Then, cell pellet was resuspended in 50 µL of 1X SDS-PAGE sample buffer and frozen at 
−20 °C. For induction, IPTG was added to the remaining culture to a final concentration of 0.3 mM 
and the culture was incubated at 37 °C and 250 rpm shaking for 4 h. At each hour after induction a 
sample of 1 mL was taken and prepared for SDS-PAGE analysis.  
4.4. Expression and Optimization of Adiponectin Production by P. pastoris  
The recombinant X-33 single colony was inoculated in BMGY medium and grown at 30 °C until 
OD600 was 2–6. The cell pellet was resuspended in BMMY media (or BGMY medium for control 
culture) at OD600 = 1, and grown at 30 °C with shaking at 220 rpm. Methanol induction was carried out 
at 12 h intervals to a final concentration 0.5%, and harvesting was carried out at 12, 24, 36, 48, 60, 72, 
84 and 96 h after induction. Glycerol was added to the BMGY medium as a substitute for methanol. 
Supernatants were collected from harvested cultures and secreted proteins were analysed by  
SDS-PAGE and western blot using anti-ADP antibody. In another experiment, five tubes containing 
10 mL YPD medium were inoculated with single recombinant X-33 colony and incubated for 16–18 h 
until OD600 reached 2 to 6. For growth phase culture, the harvested cells were transferred to five  
250 mL flasks containing 50 mL BMGY media and cultured as previously described until OD600 
reached 2 to 6. Next, the harvested cells were resuspended in five 1 L flasks containing 200 mL 
BMMY media, and cultured until OD600 = 1. For induction phase, 100% methanol was added to a final 
concentration of 0.5% every 12 h for 60 h at 30 °C in a shaking incubator (250–300 rpm). To 
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precipitate the secreted P-ADP, three volumes of acetone were added to the collected supernatants 
followed by incubation at −20 °C overnight. The dissolved protein was resuspended with PBS buffer, 
subsequently purified by affinity chromatography and quantified using the Bradford method.  
4.5. Protein Purification 
4.5.1. E-ADP Purification by Amylose Resin Column 
The amylose resin was poured into a disposable polypropylene column of 25 mL volume (BioRad 
Econo-Pac™, U.S.A.). The bed volume was 5 mL and the column volume was 20 mL. The column 
was washed with 8 column volume of column buffer (20 mM Tris-HCl, 200 mM NaCl and 1 mM 
EDTA). Then, the crude extract was loaded into the column at a flow rate about 1 mL/min. The 
column was turned off for 15 min to enable optimal binding between the fusion protein and the 
amylose resin. Later, the column was washed with 12 column volume of column buffer. In order to 
elute the bound protein, one column volume of elution buffer (column buffer with 10 mM maltose) 
was added and the fractions (3 mL) were collected and kept at −80 °C. 
4.5.2. Cleavage, Denaturing and Re-Purification of E-ADP 
First, a pilot experiment was carried out using small portion of protein sample to optimize the 
suitable time for Factor Xa ( Biolabs, UK) cleavage. Factor Xa final concentration of 1% was added to 
the protein sample, the positive control was a protein sample before purification (crude protein) 
incubated with same concentration of Factor Xa. All samples were incubated for 2, 4 and 8 h. From 
each reaction 5 μL were added to 5 μL of 2× SDS-PAGE sample buffers and saved at 4 °C.  
SDS-PAGE was applied to determine the suitable time for cleavage. Then, the pilot experiment was 
scaled up for the portion of the fusion protein to be cleaved. Guanidine hydrochloride was added to the 
sample to a final concentration of 6 M. Later, the sample was dialysed against 100 sample volumes 
column buffer (20 mM Tris-HCl, 200 mM NaCl and 1 mM EDTA) three times for 2 h each. In order to 
remove the rest of maltose binding protein, the fusion protein cleavage mixture was loaded onto the 
hydroxyapatite column (BioRad Econo-Pac™, U.S.A.). The column was washed with 80 mL of  
20 mM sodium phosphate, 200 mM NaCl (pH 7.2). The protein mixture was eluted with 0.5 M Na 
phosphate (pH 7.2). The collected fractions were loaded onto amylose column and the flow through 
was collected that should be free of maltose binding protein (MBP).  
4.5.3. P-ADP Purification by Nickel Column 
Protein samples were purified by His GraviTrap™ Flow (Amersham Biosciences, USA) column 
containing precharged Ni Sepharose™ 6 Fast. The column was normalized with 8 mL of phosphate 
buffer (20 mM sodium phosphate buffer and 500 mM NaCl, pH 7.4). The sample (4 mL) was loaded 
into the column and the column was washed with 10 mL of binding buffer (phosphate buffer 
containing 20 mM imidazole, pH 7.4). The recombinant protein was eluted with 4 mL of elution buffer 
(phosphate buffer containing 200 mM imidazole, pH 7.4).  
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4.6. SDS-PAGE and Western Immunoblotting 
Purified P-ADP and E-ADP proteins were separated by SDS-PAGE in denaturing and non-
denaturing (with and without heat and reducing agents) conditions. The proteins were then transferred 
onto polyvinylidene fluoride membrane as described elsewhere [17]. In brief, protein samples were 
loaded into 12% gels SDS-PAGE, and then transferred to a nitrocellulose membrane (1 h, 100 V). 
Following transfer, the membrane was blocked in Tris Buffered Saline with Tween-20 containing  
50 g/L skimmed milk for 2 h, and then incubated with adiponectin monoclonal antibody (abcam, UK) 
for 2 h at room temperature. The strips were washed three times with Tris Buffered Saline (15 min 
each time) and then incubated with mouse anti-IGg antibody conjugated with alkaline phosphatase 
(Sigma, USA) for 2 h, washed again with Tris Buffered Saline as described previously, and finally 
developed with Western Blue
®
 stabilized substrate (Promega, USA). 
4.7. Effect of Recombinant Adiponectin on Blood Glucose and Lipids 
Female ICR mice were used to compare the biological activity of ADP expressed in P. pastoris and 
E. coli. Animals were obtained from the Animal House, Faculty of Medicine, University of Malaya in 
Kuala Lumpur (Ethics No. PM 07/05/2010 MAA (a) (R). Following overnight fasting, animals  
(3 groups, n = 6 each) were gavaged with high fat-sucrose diet. Immediately after feeding, the first 
group was injected with 0.9 mg/kg of bodyweight P-ADP. The second group was injected with  
0.9 mg/kg of bodyweight E-ADP and the final group was injected with 0.3 mL saline for experiment 
control. After one hour of the first injection (or one hour after feeding) a second dose of treatment was 
given to all mice (the total amount of P-ADP and E-ADP being administered for each mouse = 
1.8 mg/kg bodyweight). Blood glucose was measured with a glucometer at one hour intervals for four 
hours. In addition, blood concentration of triglyceride (TG), total cholesterol (CHOL) (Siemens, 
U.S.A.), low density lipoprotein (LDL) and high density lipoprotein (HDL) (Dade Behring, U.S.A.) 
were also measured at the end of the fourth hour of the experiment using available commercial kits.  
4.8. Statistical Analysis 
Values are expressed as means ± S.E.M. The mean value comparisons between two groups were 
performed using the Student t test. Significant differences were considered at p < 0.05. 
5. Conclusions 
It is interesting to note that the P. pastoris expression system was able to produce higher quantity 
with simple purification and higher bioactivity of ADP compared to the expression by E. coli. All 
these factors together make P. pastoris the favourable expression system to produce recombinant 
human adiponectin for treatment of type II diabetes and cardiovascular diseases. 
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